Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A Yorkshireman offering to spend money. I smell a rat.
RK,
Sorry ...just saw your reply...yes agreed options to diversify virus testing are sig. upwards and onwards., happily buy you all a fish bash in the Wetherby Whaler if and when £10 reached....
Regards
RK,-
"Of course right now with the best on the planet results every LFD manufacturer will want to be working with Avacta to deliver tests to there own markets and global sales may well be much greater than anyone could imagine. the numbers of cases in the US, Brazil and India are growing so quickly but the rest of the world needs testing too and safety on the planet is determined by a simple test and we are looking like we will be right on the top of every governments wish list to have tests"
I think most governments who's nations economies include LFD manufacturers will want to know from those manufacturers, what else the govnt can do in order to get LFD manufacturers making the POC test.
The international clamour (from govnts as well as LFD manufacturers) once tests are approved will be deafening, and the situation will need professional management.
This frees up schools, industry and commerce, and allows the re-opening of parts of the economy most likely to be closed due to pandemic, so there is a lot to lose if your economy is not one of the first to be 'liberated', ie, those nations who do not have a manufacturer of LFD tests.
I have recently mentioned licensing, and I feel it may be the only solution, because after LFT approval, the situation will become chaotic.
From a value perspective a split would make sense - most potential acquirers are one or the other. Maybe they will spin the pharma bit off?
Sir Al will have a better idea of the margins and f/c for the Dx. I suspect he wants to get this launched as proof of concept and be able to point at one of those hockey stick graphs. I get the impression is heart is in the pharma bit so can see Abbott or Danaher making an offer he cannot refuse.
I see £2.2B - any advance?
'could we see a T/O of the diagnostic div?'
I wondered at the time whether that was the real purpose behind the LSTM tie up
I suspect we both therefore intend to exit late November or £9.90
Insert big winky yellow head
Interesting thoughts Ken. I'm sanity checking my own
If "Avacta test, we can expect every reason for simple rapid tests to be come the only way to test" why are we developing a BAMS test.
In terms of Iron fillings and magnets do we have an indication of affinity - particularly compared to antibodies. My understanding is that all LFDs rely on binding reagents ?
Agree £10+ before Xmas - otherwise I'm going to have to cancel the kids holiday and not eat for a month
Nice to read your posts RK , very informative....
@yorkshirepragma I think that with the potential news of exceptional S&S numbers and a highly likely result from the POC LFD in less than 10 minutes and possibly in less than 5 minutes we can expect it to make global news! To this point, the only truly accurate test has been a PCR type test, Antigen tests have so far been a second best option. With the Avacta test, we can expect every reason for simple rapid tests to be come the only way to test. The likely publicity I am sure will be covered by media around the world. We are all expecting less than 10 minutes, but if the production test breaks 5 minutes then no company will get close. The Affimer technology using the specific target Affimers which will be like iron fillings attracted to a magnet. So I expect the result to be very quick indeed. I am sure that is why Alastair Smith said they are very pleased with the results from the pilot test and they await the first production LFD tests to see how close the match is to the pilot. If it is as good they will have a product that will change Covid-19 testing for a long time to come.
Following this it makes me wonder what other test devices and viruses will Avacta target in the future, there are many other viruses which could use the same technology using Affimers and the opportunity to grow this market far beyond Covid-19.
Of course right now with the best on the planet results every LFD manufacturer will want to be working with Avacta to deliver tests to there own markets and global sales may well be much greater than anyone could imagine. the numbers of cases in the US, Brazil and India are growing so quickly but the rest of the world needs testing too and safety on the planet is determined by a simple test and we are looking like we will be right on the top of every governments wish list to have tests let alone the private sector which will be targeted via MEDUSA19.
Add the BAMs lab testing which is likely to discover mutations as the virus changes, which will allow Avacta to modify the LFD if the Affimer attraction needs changing and Avacta will stay ahead.
Then bring in the Virus neutralising technology with are partnership with Daewoong and you have a full Covid-19 tool back to detect and fight the virus from a small but soon to be known globally British Biotech company.
Cheers, Rich
Is S&S exceeds new FDA template requirements could we see a T/O of the diagnostic div?
Many US Companies will see the takeup of the LFT (as opposed to PCR) and the real value of what Awacta have in affimer diagnostics.
Test, test, test
RK,
Yes, that would be an admirable outcome. Just adding one pertinent point, that the improved ‘profile’ will likely be driven by all the no doubt good PR around the affirmed LFT technology application. Stateside interest is notoriously fickle , but in Avactas case we can expect it to resoundingly positive.
USA interest will have a large part in future share price . I suspect you’re right in hyper £10 prediction should the interest come in strong...
Best Wishes
Like the sound of £10, by year end hopefully don't want to wait too long!
Good afternoon all, I expect with excellent S&S results and forward orders for BMS the SP to move into the £2.00 to £2.20 window and with the LFD news with forward sales a jump into the £4 to £5 mark. If the virus continues its path as unfortunately expected we should see multiple new partnerships and production capacity and global sales for BAMS and LFD and the share price heading to circa £10 around Christmas time.
Other news and developments may accelerate this in my opinion.
Cheers Rich
Impossible to say but I'd fully expect it to break through the 200p barrier and reach new highs.
Once we get it to market, that's when we will see real gains
Roof
Wiggly. Does "through the roif" count as a prediction?
All the best.
Any prediction on the Share Price reaction should AVCT announce clinically validated accuracy at >99%?